Compile Data Set for Download or QSAR
Report error Found 53 Enz. Inhib. hit(s) with all data for entry = 8380
Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Human)
Astellas Pharma

US Patent
LigandPNGBDBM244220(US9428501, 7)
Affinity DataEC50:  8.30nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Human)
Astellas Pharma

US Patent
LigandPNGBDBM244235(US9428501, 66)
Affinity DataEC50:  2.80nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Human)
Astellas Pharma

US Patent
LigandPNGBDBM244234(US9428501, 58)
Affinity DataEC50:  0.860nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Human)
Astellas Pharma

US Patent
LigandPNGBDBM244233(US9428501, 57)
Affinity DataEC50:  1.80nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Human)
Astellas Pharma

US Patent
LigandPNGBDBM244232(US9428501, 50)
Affinity DataEC50:  14nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Human)
Astellas Pharma

US Patent
LigandPNGBDBM244231(US9428501, 49)
Affinity DataEC50:  6.5nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Human)
Astellas Pharma

US Patent
LigandPNGBDBM244230(US9428501, 44)
Affinity DataEC50:  5.20nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Human)
Astellas Pharma

US Patent
LigandPNGBDBM244229(US9428501, 38)
Affinity DataEC50:  13nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Human)
Astellas Pharma

US Patent
LigandPNGBDBM244228(US9428501, 37)
Affinity DataEC50:  10nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Human)
Astellas Pharma

US Patent
LigandPNGBDBM244227(US9428501, 36)
Affinity DataEC50:  5.10nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Human)
Astellas Pharma

US Patent
LigandPNGBDBM244226(US9428501, 35)
Affinity DataEC50:  3.60nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Human)
Astellas Pharma

US Patent
LigandPNGBDBM244225(US9428501, 23)
Affinity DataEC50:  19nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Human)
Astellas Pharma

US Patent
LigandPNGBDBM244224(US9428501, 19)
Affinity DataEC50:  10nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Human)
Astellas Pharma

US Patent
LigandPNGBDBM244223(US9428501, 18)
Affinity DataEC50:  3nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Human)
Astellas Pharma

US Patent
LigandPNGBDBM244222(US9428501, 14)
Affinity DataEC50:  34nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Human)
Astellas Pharma

US Patent
LigandPNGBDBM244221(US9428501, 8)
Affinity DataEC50:  13nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Human)
Astellas Pharma

US Patent
LigandPNGBDBM244219(US9428501, 1)
Affinity DataEC50:  24nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Human)
Astellas Pharma

US Patent
LigandPNGBDBM244236(US9428501, 69)
Affinity DataEC50:  1.80nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

Target5'-AMP-activated protein kinase catalytic subunit alpha-2(Human)
Astellas Pharma

US Patent
LigandPNGBDBM244237(US9428501, 79)
Affinity DataEC50:  3.30nMT: 2°CAssay Description:In order to make MDA-MB-453 cell become 15000 cells per well, each 36 μl was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244234(US9428501, 58)
Affinity DataIC50: 0.550nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244233(US9428501, 57)
Affinity DataIC50: 0.650nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244226(US9428501, 35)
Affinity DataIC50: 1.80nMpH: 7.5Assay Description:Human PIK3CA mutation-positive breast cancer cell line MDA-MB-453 cells were subcutaneously implanted into nude mice, MDA-MB-453 tumor was excised, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244223(US9428501, 18)
Affinity DataIC50: 2.5nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244231(US9428501, 49)
Affinity DataIC50: 2.80nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244236(US9428501, 69)
Affinity DataIC50: 3.20nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244232(US9428501, 50)
Affinity DataIC50: 4nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244230(US9428501, 44)
Affinity DataIC50: 4.20nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244226(US9428501, 35)
Affinity DataIC50: 5.20nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244235(US9428501, 66)
Affinity DataIC50: 6.20nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244223(US9428501, 18)
Affinity DataIC50: 7.10nMpH: 7.5Assay Description:Human PIK3CA mutation-positive breast cancer cell line MDA-MB-453 cells were subcutaneously implanted into nude mice, MDA-MB-453 tumor was excised, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244222(US9428501, 14)
Affinity DataIC50: 7.60nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244237(US9428501, 79)
Affinity DataIC50: 7.80nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244229(US9428501, 38)
Affinity DataIC50: 8.10nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244224(US9428501, 19)
Affinity DataIC50: 8.5nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244228(US9428501, 37)
Affinity DataIC50: 8.90nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244227(US9428501, 36)
Affinity DataIC50: 11nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244219(US9428501, 1)
Affinity DataIC50: 12nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244220(US9428501, 7)
Affinity DataIC50: 12nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244233(US9428501, 57)
Affinity DataIC50: 12nMpH: 7.5Assay Description:Human PIK3CA mutation-positive breast cancer cell line MDA-MB-453 cells were subcutaneously implanted into nude mice, MDA-MB-453 tumor was excised, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244231(US9428501, 49)
Affinity DataIC50: 18nMpH: 7.5Assay Description:Human PIK3CA mutation-positive breast cancer cell line MDA-MB-453 cells were subcutaneously implanted into nude mice, MDA-MB-453 tumor was excised, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244236(US9428501, 69)
Affinity DataIC50: 22nMpH: 7.5Assay Description:Human PIK3CA mutation-positive breast cancer cell line MDA-MB-453 cells were subcutaneously implanted into nude mice, MDA-MB-453 tumor was excised, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244221(US9428501, 8)
Affinity DataIC50: 26nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244228(US9428501, 37)
Affinity DataIC50: 29nMpH: 7.5Assay Description:Human PIK3CA mutation-positive breast cancer cell line MDA-MB-453 cells were subcutaneously implanted into nude mice, MDA-MB-453 tumor was excised, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244225(US9428501, 23)
Affinity DataIC50: 40nMAssay Description:In order to make human PIK3 CA mutation-positive breast cancer cell line MDA-MB-453 cells become 500 cells per well in a 384 well non-adhesive plate ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244219(US9428501, 1)
Affinity DataIC50: 41nMpH: 7.5Assay Description:Human PIK3CA mutation-positive breast cancer cell line MDA-MB-453 cells were subcutaneously implanted into nude mice, MDA-MB-453 tumor was excised, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244227(US9428501, 36)
Affinity DataIC50: 55nMpH: 7.5Assay Description:Human PIK3CA mutation-positive breast cancer cell line MDA-MB-453 cells were subcutaneously implanted into nude mice, MDA-MB-453 tumor was excised, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244229(US9428501, 38)
Affinity DataIC50: 59nMpH: 7.5Assay Description:Human PIK3CA mutation-positive breast cancer cell line MDA-MB-453 cells were subcutaneously implanted into nude mice, MDA-MB-453 tumor was excised, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244220(US9428501, 7)
Affinity DataIC50: 75nMpH: 7.5Assay Description:Human PIK3CA mutation-positive breast cancer cell line MDA-MB-453 cells were subcutaneously implanted into nude mice, MDA-MB-453 tumor was excised, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244221(US9428501, 8)
Affinity DataIC50: 83nMpH: 7.5Assay Description:Human PIK3CA mutation-positive breast cancer cell line MDA-MB-453 cells were subcutaneously implanted into nude mice, MDA-MB-453 tumor was excised, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

LigandPNGBDBM244230(US9428501, 44)
Affinity DataIC50: 87nMpH: 7.5Assay Description:Human PIK3CA mutation-positive breast cancer cell line MDA-MB-453 cells were subcutaneously implanted into nude mice, MDA-MB-453 tumor was excised, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2017
Entry Details
Go to US Patent

Displayed 1 to 50 (of 53 total ) | Next | Last >>
Jump to: